Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 16h05 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs
07 sept. 2022 07h30 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results
08 août 2022 16h01 HE
|
Praxis Precision Medicines, Inc.
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide...
Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference
03 août 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
06 juin 2022 07h45 HE
|
Praxis Precision Medicines, Inc.
Aria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus resources on Movement Disorders and Epilepsy franchises extends cash runway into 2024 ...
Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone
23 mai 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at Upcoming Investor Conferences
11 mai 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
09 mai 2022 16h01 HE
|
Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results...
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients
09 mai 2022 16h01 HE
|
Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by...
Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference
04 mai 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...